| Name | DZ2002 |
| Description | DZ2002, an orally active, reversible, and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), exhibits significant immunosuppressive activity. It effectively prevents experimental dermal fibrosis by reversing the profibrotic phenotype in multiple cell types, making it useful for studying autoimmune diseases like lupus syndrome and systemic sclerosis. |
| In vitro | DZ2002 (0.1, 1, 10 µM; 96 h) inhibits the mixed lymphocyte reaction (MLR) response, IL-12 and TNF-α production from both mouse peritoneal exudate cells and human THP-1 cells (24 h), and expression of B7 (CD80/CD86) on differentiated THP-1 cells (64 h) [1]. |
| In vivo | DZ2002 (2, 10, 50 mg/kg; i.p.; twice) blocks the DNFB-induced DTH response—a Th1 cell-mediated immune response with high IL-12 expression and significant macrophage involvement. DZ2002 (0.08, 2 mg/kg; i.p.; daily for 7 days) significantly suppresses delayed-type hypersensitivity and antibody secretion[1]. DZ2002 (50, 100 mg/kg; p.o.; daily for 4 weeks) exhibits a potent anti-fibrotic effect on dermal fibrosis by reducing collagen production, enhancing its degradation, and regulating various soluble factors in SSc mice model[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (179.11 mM), Sonication is recommended.
|
| Keywords | DZ-2002 | DZ2002 | DZ 2002 |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Ethyl linoleate | Hyaluronic acid sodium (MW 20 kDa) | Gluconate Calcium | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | NF-κB Signaling Compound Library | Bioactive Compound Library | JAK-STAT Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | MAPK Inhibitor Library |
United States
